Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India

Rishi, Pukhraj; Manchegowda, Pradeep T; Gondhale, Harshal; Rishi, Ekta; Das, Kalpita; Krishnakumar, Subramanian; Raja, T; Biswas, Jyotirmay

doi:10.1007/s10792-021-01805-1

Cited by 7 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment resulted in significant vitreous haze reduction and improvement of VA without any severe side effects over a median follow-up time of 565 days. Rishi et al 16 treated 12 eyes of seven patients with VRL with IVR. After a mean of six injections per eye, all patients had a complete response at a mean of 8 months.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intravitreal Melphalan Injection as a Second-line Local Therapy in Vitreoretinal Lymphoma: Case series

Beser,

Demirci

2023

Retina

View full text Add to dashboard Cite

Purpose: To evaluate the effectiveness and safety of intravitreal Melphalan(IVM) injection therapy in vitreoretinal lymphoma(VRL). Methods: Eight eyes of 5 biopsy-proven VRL patients who were treated with IVM injection as a second-line therapy after intravitreal Methotrexate(IVMTX) and Rituximab(IVR) injections were retrospectively evaluated between January 2011 and March 2023. Results: The medical records of five VRL patients (mean age of 62 years at the diagnosis) including four(80%) females and one(20%) male were retrospectively analyzed. Three patients(60%) either had a history of central nervous lymphoma or developed it during the follow-up. Patients were previously treated with a mean of 5 cycles of monthly IVMTX and IVR injections. All eyes showed complete response by the disappearance of vitreal and/or subretinal neoplastic cells within six weeks after IVM injections(range, 1-4 injections/eye). Of 12 IVM injections, three(25%) injections were associated with macular edema diagnosed on optical coherence tomography at one-month follow-up and resolved spontaneously within 5 months. The IVM administration induced new retinal pigment epithelium changes in 3 eyes(37%). Conclusion: IVM injection may be effective in the management of VRL as second-line local therapy. Randomized clinical trials with larger numbers of patients are needed to establish the efficacy, treatment protocol, and safety of IVM injection.

show abstract

Section: Discussionmentioning

confidence: 99%

“…They observed recurrence in three patients (25%). 16 However, there is limited information on the treatment of patients who developed recurrence after external beam radiotherapy, IVMTX, and IVR as a second-line therapy.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal Melphalan Injection as a Second-line Local Therapy in Vitreoretinal Lymphoma: Case series

Beser,

Demirci

2023

Retina

View full text Add to dashboard Cite

show abstract

“…In recent years, local treatment including intraocular chemotherapy and ocular radiotherapy has been more widely used in practice [108][109][110]. Either systemic or local treatment can alleviate the symptoms and intraocular tumors [109,[111][112][113][114]. However, outcomes including PFS, failure-free survival (FFS), OS, CNS/intraocular recurrence vary across studies.…”

Section: Treatmentmentioning

confidence: 99%

Evidence-based expert consensus on the management of primary central nervous system lymphoma in China

et al. 2022

View full text Add to dashboard Cite

Primary central nervous system lymphoma (PCNSL) is a type of central nervous system restricted non-Hodgkin lymphoma, whose histopathological diagnosis is majorly large B cell lymphoma. To provide specific, evidence-based recommendations for medical professionals and to promote more standardized, effective and safe treatment for patients with PCNSL, a panel of experts from the Chinese Neurosurgical Society of the Chinese Medical Association and the Society of Hematological Malignancies of the Chinese Anti-Cancer Association jointly developed an evidence-based consensus. After comprehensively searching literature and conducting systematic reviews, two rounds of Delphi were conducted to reach consensus on the recommendations as follows: The histopathological specimens of PCNSL patients should be obtained as safely and comprehensively as possible by multimodal tomography-guided biopsy or minimally invasive surgery. Corticosteroids should be withdrawn from, or not be administered to, patients with suspected PCNSL before biopsy if the patient’s status permits. MRI (enhanced and DWI) should be performed for diagnosing and evaluating PCNSL patients where whole-body PET-CT be used at necessary time points. Mini-mental status examination can be used to assess cognitive function in the clinical management. Newly diagnosed PCNSL patients should be treated with combined high-dose methotrexate-based regimen and can be treated with a rituximab-inclusive regimen at induction therapy. Autologous stem cell transplantation can be used as a consolidation therapy. Refractory or relapsed PCNSL patients can be treated with ibrutinib with or without high-dose chemotherapy as re-induction therapy. Stereotactic radiosurgery can be used for PCNSL patients with a limited recurrent lesion who were refractory to chemotherapy and have previously received whole-brain radiotherapy. Patients with suspected primary vitreoretinal lymphoma (PVRL) should be diagnosed by vitreous biopsy. PVRL or PCNSL patients with concurrent VRL can be treated with combined systemic and local therapy.

show abstract

Masquerade/ocular lymphoma

Deák,

El-Shabrawi

2024

Spektrum Augenheilkd.

View full text Add to dashboard Cite

ZusammenfassungIntraokulare Lymphome und insbesondere vitreoretinale Lymphome (VRL) gehören zu den am schwierigsten zu diagnostizierenden ophthalmologischen Erkrankungen, da sie sich als eine Reihe häufigerer Augenerkrankungen tarnen können und die Labordiagnostik zu ihrem Nachweis häufig falsch-negative Ergebnisse liefert. In dieser aktuellen Übersichtsarbeit diskutieren wir die Ätiologie der VRL und geben eine aktuelle Zusammenfassung der diagnostischen und therapeutischen Möglichkeiten.

show abstract

Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India

Cited by 7 publications

References 28 publications

Intravitreal Melphalan Injection as a Second-line Local Therapy in Vitreoretinal Lymphoma: Case series

Intravitreal Melphalan Injection as a Second-line Local Therapy in Vitreoretinal Lymphoma: Case series

Evidence-based expert consensus on the management of primary central nervous system lymphoma in China

Masquerade/ocular lymphoma

Contact Info

Product

Resources

About